KPV (Lysine-Proline-Valine) is derived from the C-terminus of alpha-MSH. It retains anti-inflammatory potency without melanogenic activity. It directly enters epithelial cells and reaches the nucleus to modulate NF-u03baB and suppress TNF-u03b1, IL-1u03b2, and IL-6 production.
Overview
Reconstitution Table (2 mL mL BAC water u2192 2 mg)
| Condition | Dose | Route |
| Systemic inflammation | 500 mcg daily | SC injection |
| IBD / GI targeting | 500 mcgu20131 mg daily | Oral (in gelatin caps) |
| Topical skin use | 0.01u20130.1% | Topical cream |
Reconstitute 2 mg with 2 mL BAC water u2192 1,000 mcg/mL. 500 mcg = 5 Units on a U-100 syringe.
Oral and topical formulations of KPV are being studied. SC injection gives reliable systemic bioavailability. Research use only.
Potential Benefits & Side Effects
Potential Benefits
- IBD and Crohn's disease improvement
- Psoriasis and eczema reduction
- Wound healing acceleration
- Reduction in systemic inflammatory markers
Possible Side Effects
- Mild injection-site irritation
- Temporary skin flushing (topical, uncommon)
Storage Instructions
Lyophilized Powder
- Short-term (<3 months): Refrigerate at 2u00b0Cu20138u00b0C
- Long-term: Freeze at u221220u00b0C or lower
- Protect from light and moisture
- Allow vial to reach room temperature before opening
Reconstituted Solution
- Refrigerate at 2u00b0Cu20138u00b0C u2014 do not freeze
- Use within 28 days when reconstituted with BAC water
- Always use sterile technique when drawing doses
References
Goumon Y. et al. (2000)
The C-terminal tripeptide of alpha-MSH is a potent anti-inflammatory agent
View SourceImportant Note
This protocol guide is for educational and research purposes only. It is not medical advice. Always consult a qualified healthcare professional before using any peptide compound.